ERBB2 and breast carcinoma: For example, targeted therapies have established intracranial activity in patients with Her2-positive breast cancer BM (10, 11), ALK-rearranged (12, 13) or EGFR-mutated NSCLC BM (40) and for BRAF V600E mutated melanoma BM (41).